ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Adverse events"

  • Abstract Number: 462 • 2014 ACR/ARHP Annual Meeting

    Infections and Gastrointestinal Side Effects in a Comparison of Rheumatoid Arthritis Therapies

    Bei-Hung Chang1,2, Lien Quach1, Mary Brophy3, Keri Hannagan4, Edward C. Keystone5, Ted R. Mikuls6 and James R. O'Dell7, 1VA Boston Healthcare System, Boston, MA, 2Qualitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, 3VA Boston Heathcare System, Boston, MA, 4MAVERIC, VA Boston Heathcare System, Boston, MA, 5Medicine, University of Toronto, Toronto, ON, Canada, 6Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 7Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE

    Background/Purpose TNF inhibitors and combinations of conventional disease-modifying antirheumatic drugs are commonly added to treat methotrexate non-responsive rheumatoid arthritis patients. In the 48-week double blind,…
  • Abstract Number: 478 • 2014 ACR/ARHP Annual Meeting

    Adverse Events and Infections in Patients with Rheumatoid Arthritis Treated with Conventional Drugs or Biologic Agents: A Real World Study

    Christos E. Lampropoulos1, Philippos Orfanos2, Vasiliki-Kalliopi Bournia3, Theofilos P. Karatsourakis4, Clio P. Mavragani5, Dimitrios Pikazis4, Menelaos N. Manoussakis6, Athanasios G. Tzioufas4, Haralampos M. Moutsopoulos7 and Panayiotis G. Vlachoyiannopoulos3, 1Department of Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, 2Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National University of Athens, Athens, Greece, 3First Department of Propedeutic Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, 4Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, 5Department of Experimental Physiology, School of Medicine, University of Athens, Athens, Greece, Athens, Greece, 6Pathophysiology, School of Medicine, National University of Athens, Greece, Athens, Greece, 7Department of Pathophysiology, School of Medicine, University of Athens, Athens, Greece

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory disease with joint destruction and permanent disability. Biologic agents (BAs) offer a better outcome when disease is…
  • Abstract Number: 477 • 2014 ACR/ARHP Annual Meeting

    Leflunomide Use Is Not Associated with an Increased Risk of Lung Disease in Rheumatoid Arthritis: A Meta-Analysis of Randomised Controlled Trials

    Richard Conway1, Candice Low2, Robert J. Coughlan1, Martin O'Donnell3 and John J. Carey1, 1Rheumatology, Galway University Hospitals, Galway, Ireland, 2Medicine, St. James Hospital, Dublin, Ireland, 3Clinical Research Facility, Galway University Hospitals, Galway, Ireland

    Background/Purpose Leflunomide is an effective treatment for rheumatoid arthritis. An association between pulmonary adverse events, in particular interstitial lung disease, and leflunomide use has been…
  • Abstract Number: 471 • 2014 ACR/ARHP Annual Meeting

    Improving of Safety in Treatment with Biologics during First Seven-Years Experiences; Long-Term Results from Observational Cohort Study of Clinical Practice Using Multicenter Registry in Japan

    Toshihisa Kojima1, Nobunori Takahashi1, Koji Funahashi2, Shuji Asai2, Yutaka Yoshioka2, Kenya Terabe2, Nobuyuki Asai2,3, Toki Takemoto2, Naoki Ishiguro1, Atsushi Kaneko4, Yuji Hirano5, Yuichiro Yabe6 and Yasuhide Kanayama7, 1Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 2Nagoya University Hospital, Nagoya, Japan, 3Nagoya Univeristy Hospital, Nagoya, Japan, 4Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan, 5Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, 6Rheumatology, JCHO Tokyo Shinjuku Medical Center, Tokyo, Japan, 7Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan

    Background/Purpose: Many evidences including clinical trials of biologics lead us earlier and more aggressive treatment strategy for patients with rheumatoid arthritis (RA). It is stated…
  • Abstract Number: 468 • 2014 ACR/ARHP Annual Meeting

    Identification of Baseline Risk Factors for Adverse Events in Certolizumab Pegol Treated Rheumatoid Arthritis Patients

    Boulos Haraoui1, John Wade2, Marc de Longueville3, Pauline Ralston4 and Jeffrey R. Curtis5, 1Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, 2Division of Rheumatology, University of British Columbia, and Vancouver General Hospital, Vancouver, BC, Canada, 3SA Global Medical Affairs, UCB Pharma, Brussels, Belgium, 4Giant Professional Ltd, London, United Kingdom, 5Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose Despite efficacy of anti-tumor necrosis factors (anti-TNFs) in treating chronic immune conditions, some patients (pts) report serious adverse events (SAEs) highlighting a need to…
  • Abstract Number: 71 • 2014 ACR/ARHP Annual Meeting

    Prevalence of Pain Reporting in Different Ethnic Groups in the UK: Results from a Large Biobank

    Marcus Beasley1, Gareth T. Jones1, Tatiana Macfarlane2 and Gary J. Macfarlane1, 1Musculoskeletal Research Collaboration (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, 2Dental School, University of Aberdeen, Aberdeen, United Kingdom

    Background/Purpose: Very large epidemiological studies designed to investigate genetic and environmental influences on disease, known as ‘biobanks' can be used to look at associations between…
  • Abstract Number: 440 • 2013 ACR/ARHP Annual Meeting

    Cardiovascular Safety Findings In Rheumatoid Arthritis Patients Treated With Tofacitinib, A Novel, Oral Janus Kinase Inhibitor

    C. Charles-Schoeman1, P Wicker2, M. A. Gonzalez-Gay3, S. P. Wood4, M.G. Boy4, J. Geier5, D. Gruben4, K. Soma4 and R. Riese4, 1Medicine-Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, 2PW Consulting LLC, Mystic, CT, 3Reumatologia, Hospital Marques De Valdecilla, Santander, Spain, 4Pfizer Inc, Groton, CT, 5Pfizer Inc, New York, NY

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we evaluated the cardiovascular (CV) event rates and…
  • Abstract Number: 173 • 2013 ACR/ARHP Annual Meeting

    HLA-DRB1*08:02 Is Associated With Bucillamine-Induced Proteinuria In Japanese Rheumatoid Arthritis Patients: A Case-Control Study

    Hiroshi Furukawa1, Shomi Oka1, Kota Shimada2, Shoji Sugii2, Atsushi Hashimoto3, Akiko Komiya1, Naoshi Fukui1, Taiichiro Miyashita4, Kiyoshi Migita4, Akiko Suda5, Shouhei Nagaoka6, Naoyuki Tsuchiya7 and Shigeto Tohma1, 1Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, 2Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, 3Department of Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, 4Clinical Research Center, Nagasaki Medical Center, National Hospital Organization, Omura, Japan, 5Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, 6Department of Rheumatology, Yokohama Minami Kyousai Hospital, Yokohama, Japan, 7Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

    Background/Purpose: Bucillamine (Buc) is one of the commonly used disease-modifying anti-rheumatic drugs (DMARDs) in Japan. Drug-induced proteinuria can occur in rheumatoid arthritis (RA) patients treated…
  • Abstract Number: 442 • 2013 ACR/ARHP Annual Meeting

    Tolerability and Non-Serious Adverse Events In Rheumatoid Arthritis Patients Treated With Tofacitinib As Monotherapy Or In Combination Therapy

    A. Dikranian1, K. Soma2, R. Riese2, D. Gruben2 and T. V. Jones3, 1San Diego Arthritis Medical Clinic, San Diego, CA, 2Pfizer Inc, Groton, CT, 3Pfizer Inc, Collegeville, PA

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Tolerability remains an ill-defined construct in clinical trials.…
  • Abstract Number: 2626 • 2013 ACR/ARHP Annual Meeting

    Infliximab For Sight-Threatening and Refractory Uveitis Of Behcet’s Syndrome

    Vedat Hamuryudan1, Gulen Hatemi2, Yilmaz Ozyazgan2, Didar Ucar2, Sebahattin Yurdakul2, Emire Seyahi2, Koray Tascilar2, Serdal Ugurlu2 and Hasan Yazici3, 1Division of Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, 2Cerrahpasa Medical Faculty University of Istanbul, Behcet's Syndrome Research Center, Cerrahpasa Medical Faculty University of Istanbul, Istanbul, Turkey, 3Cerrahpasa Medical Faculty University of Istanbul, Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey

    Background/Purpose: Uncontrolled studies suggest a beneficial effect of infliximab in the treatment of severe uveitis of BS. The majority of these studies had short observation…
  • Abstract Number: 459 • 2013 ACR/ARHP Annual Meeting

    Transaminase Levels and Hepatic Events Observed During Tocilizumab Treatment: Pooled Analysis Of Long-Term Clinical Trial Safety Data In Patients With Rheumatoid Arthritis

    MC Genovese1, Joel M. Kremer2, Ronald F. van Vollenhoven3, Rieke Alten4, Juan José Scali5, Ariella Kelman6, Lucy Rowell7 and Laura Pitts7, 1Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, 2Center for Rheumatology, Albany Medical College, Albany, NY, 3Karolinska Institute, Stockholm, Sweden, 4Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, 5Durand University Hospital, Buenos Aires, Argentina, 6Genentech, South San Francisco, CA, 7Roche, Welwyn Garden City, United Kingdom

    Background/Purpose: The interleukin-6 receptor inhibitor tocilizumab (TCZ) has demonstrated efficacy in improving signs/symptoms, reducing joint damage, and improving function and is well tolerated in patients…
  • Abstract Number: 2628 • 2013 ACR/ARHP Annual Meeting

    Immunogenicity Of Infliximab Modulates Efficacy and Safety In Behcet’s Disease Patients With Uveitis

    Mitsuhiro Takeno1, Kayo Terauchi1, Yohei Kirino1,2, Ryusuke Yoshimi1, Nobuhisa Mizuki2, Etsuko Shibuya3 and Yoshiaki Ishigatsubo2, 1Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 2Yokohama City University Graduate School of Medicine, Yokohama, Japan, 3Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine, Yokohama, Japan

    Background/Purpose: Infliximab (IFX) suppresses ocular attacks in Behcet’s disease (BD) with uveitis, resulting in favorable long-term visual prognosis. However, some patients had ocular attacks which…
  • Abstract Number: 2351 • 2013 ACR/ARHP Annual Meeting

    Tocilizumab In Patients With Rheumatoid Arthritis and Rates Of Malignancy: Results From Long-Term Extension Clinical Trials

    Ronald F. van Vollenhoven1, Andrea Rubbert-Roth2, Anthony Sebba3, Benjamin Porter-Brown4, Lucy Rowell5, Pavel Napalkov6 and Devi Smart5, 1Karolinska Institute, Stockholm, Sweden, 2Med Clinic I, University of Cologne, koln, Germany, 3University of South Florida, Tampa, FL, 4Roche Products Ltd., Welwyn Garden City, United Kingdom, 5Roche, Welwyn Garden City, United Kingdom, 6Epidemiology, Genentech, South San Francisco, CA

    Background/Purpose: Malignancy is a potential risk of immunomodulatory treatments and may be increased in patients (pts) with rheumatoid arthritis (RA). The risk of malignancy was…
  • Abstract Number: 2362 • 2013 ACR/ARHP Annual Meeting

    Incidence Of Adverse Events In Patients With Rheumatoid Arthritis and Spondyloarthritis Exposed To Anti-TNF Therapy. Data From The Brazilian Registry For Monitoring Of Biologic Therapies In Rheumatic Diseases (BiobadaBrasil)

    Roberto Ranza1, David C Titton2, Valeria Vallim3, Ines Silveira4, Aline Ranzolin5, Andre Hayata6, Mirhelen M. Abreu7, Paulo Louzada-Jr8, Angela LBP Duarte5, Claiton Brenol9, Geraldo C Pinheiro10, Glaucio R Castro11, Hellen M Carvalho12, Isaias Costa13, Jose C Macieira14, Jose R Miranda15, Julio CM Bertacini16, Luis SG Barbosa17, Manoel B Bertolo18, Marcelo M. Pinheiro12, Maria F Sauma19, Marilia B Silva20, Marlene Freire21, Roberto A Toledo22 and Vander Fernandes23, 1Universidade Federal de Uberlandia, Uberlandia MG, Brazil, 2Hospital de Clínicas da UFPR, Curitiba PR, Brazil, 3Universidade Federal do Espirito Santo, Vitoria ES, Brazil, 4PUCRS, Porto Alegre RS, Brazil, 5Universidade Federal de Pernambuco, Recife PE, Brazil, 6CRO Osasco, Osasco SP, Brazil, 7Universidade Federal de São Carlos, São Carlos SP, Brazil, 8USP RP, Ribeirão Preto SP, Brazil, 9Universidade Federal do Rio Grande do Sul, Porto Alegre RS, Brazil, 10UERJ, Rio de Janeiro RJ, Brazil, 11Hospital Governador Celso Ramos, Florianopolis SC, Brazil, 12Brazilian Registry of Spondyloarthritis, São Paulo, Brazil, 13Universidade Federal MS, Campo Grande MS, Brazil, 14UFS Aracaju, Aracaju SE, Brazil, 15Artrocenter Clinica Medica, Taubate SP, Brazil, 16USP SP CDMAC, São Paulo SP, Brazil, 17Universidade Federal Mato Grosso, Cuiabá MT, Brazil, 18UNICAMP, Campinas SP, Brazil, 19UFPA, Belem PA, Brazil, 20Hospital Universitario Evangelico, Curitiba PR, Brazil, 21UFTM, Uberaba MG, Brazil, 22FUNFARP, São José do Rio Preto SP, Brazil, 23Universidade de Cuiabá, Cuiaba MT, Brazil

    Background/Purpose: The safety profile of a-TNF biologic drugs might have substantial regional differences due to geographic and socio economic factors and to epidemiology of infectious…
  • Abstract Number: 2048 • 2013 ACR/ARHP Annual Meeting

    Risk Factors For Glucocorticoids-Induced Diabetes In Patients With Rheumatic Diseases

    Takayuki Katsuyama1, Sayaka Aoki2, Ken-ei Sada3, Yuriko Yamamura1, Haruki Watanabe1, Eri Katsuyama1, Mariko Narazaki1, Noriko Tatebe1, Koichi Sugiyama1, Katsue S. Watanabe3, Hiroshi Wakabayashi1, Tomoko Kawabata1, Jun Wada4 and Hirofumi Makino3, 1Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan, 2Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 3Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan, 4Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

    Background/Purpose: Since the efficacy of glucocorticoids for various rheumatic diseases was reported, glucocorticoids are still one of the important therapeutic agents in the current treatment…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology